News
- Author:
- Becky McCall
Publish date: October 6, 2023
Taken together, the data suggest that subacute inflammation manifesting in asthma as well as the onset of asthma or an acute infection may be a pre...
News
- Author:
- Becky McCall
Publish date: October 4, 2023
“Importantly, these effects were sustained for up to 3 years, supporting the use of once weekly semaglutide for the long-term management of type 2 ...
News
- Author:
- Becky McCall
Publish date: October 4, 2023
“Demonstrating superiority over insulin lispro in terms of the so-called trio of A1c, weight loss, and hypoglycemic events, tirzepatide offers both...
News
- Author:
- Becky McCall
Publish date: October 2, 2023
The analysis estimates that an additional 17% of undiagnosed women younger than 50 years could be reclassified as having type 2 diabetes.
News
- Author:
- Becky McCall
Publish date: August 7, 2023
“The word is so stigmatized, with so much misunderstanding and misperception, some might say the only solution is to change the name.”
News
- Author:
- Becky McCall
Publish date: July 14, 2023
VIENNA – Naltrexone can be safely administered to patients with alcoho...
News
- Author:
- Becky McCall
Publish date: June 26, 2023
Scoring system was developed and validated to detect clinically significant (greater than stage 2) fibrosis in patients with NAFLD in primary care....
News
- Author:
- Becky McCall
Publish date: June 23, 2023
Two doses of resmetirom met the primary endpoints of NASH resolution and no worsening of fibrosis on liver biopsy.
News
- Author:
- Becky McCall
Publish date: June 14, 2023
The 2023 recommendations cover new treatment strategies with more ambitious goals, new data on adverse effects of chronic glucocorticoid use, and n...
News
- Author:
- Becky McCall
Publish date: June 6, 2023
Two phase 3 trials of the once-monthly SEL-212 in refractory gout achieved and maintained serum uric acid < 6 mg/dL for ≥ 80% of the final month...
News
- Author:
- Becky McCall
Publish date: June 5, 2023
The update to 2017 recommendations include targeted synthetic and biologic DMARDs for the first time.
News
- Author:
- Becky McCall
Publish date: June 5, 2023
The investigational drug, AR882, reduced serum uric acid to levels seen in people without hyperuricemia and gout.
News
- Author:
- Becky McCall
Publish date: June 2, 2023
Results of a phase 3 trial in Chinese patients with systemic lupus erythematosus showed a significantly greater response rate with telitacicept, co...
News
- Author:
- Becky McCall
Publish date: June 1, 2023
The risk for interstitial lung disease in patients with PsA during the first 5 years after starting a biologic or targeted synthetic DMARD was five...
News
- Author:
- Becky McCall
Publish date: May 24, 2023
“These studies provide encouraging proof-of-concept evidence that small tweaks in delivery apps could help many people to identify and select healt...
